My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
87.57
+0.26 (+0.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,067,933
Open
87.04
Bid (Size)
86.00 (1)
Ask (Size)
89.03 (4)
Prev. Close
87.31
Today's Range
86.36 - 88.54
52wk Range
53.56 - 92.86
Shares Outstanding
222,430,635
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Incyte (INCY) Stock Is Up, What You Need To Know
October 16, 2025
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 1.5% in the afternoon session after the company announced Health Canada's approval of its Opzelura cream for treating atopic...
Via
StockStory
Topics
Artificial Intelligence
Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000
October 14, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Performance
YTD
+25.9%
+25.9%
1 Month
+4.4%
+4.4%
3 Month
+27.0%
+27.0%
6 Month
+50.4%
+50.4%
1 Year
+32.3%
+32.3%
More News
Read More
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
October 12, 2025
From
Incyte
Via
Business Wire
JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance
October 10, 2025
Via
MarketMinute
Topics
Economy
Intellectual Property
What 14 Analyst Ratings Have To Say About Incyte
October 09, 2025
Via
Benzinga
Which S&P500 stocks are gapping on Wednesday?
October 08, 2025
Via
Chartmill
Incyte to Report Third Quarter Financial Results
October 08, 2025
From
Incyte
Via
Business Wire
2 Reasons to Like INCY and 1 to Stay Skeptical
October 02, 2025
Via
StockStory
Topics
Stocks
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
September 29, 2025
Via
MarketMinute
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 24, 2025
From
Incyte
Via
Business Wire
STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy
September 23, 2025
Via
MarketMinute
Topics
Intellectual Property
Jim Cramer Spotlights These Undervalued S&P 500 Stocks With Growth Potential Amid Skyrocketing Market
September 23, 2025
Via
Benzinga
Topics
Stocks
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
September 22, 2025
From
Incyte
Via
Business Wire
Incyte Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
September 19, 2025
Via
Benzinga
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In Children
September 19, 2025
Via
Benzinga
Incyte Corp (NASDAQ:INCY) Emerges as a Top Value Investing Candidate
September 19, 2025
Via
Chartmill
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
September 18, 2025
From
Incyte
Via
Business Wire
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
September 17, 2025
From
Incyte
Via
Business Wire
2 S&P 500 Stocks with Exciting Potential and 1 We Avoid
September 15, 2025
Via
StockStory
Topics
Stocks
Uncover the latest developments among S&P500 stocks in today's session.
September 12, 2025
Via
Chartmill
3 Unpopular Stocks That Deserve a Second Chance
September 12, 2025
Via
StockStory
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
September 10, 2025
From
Incyte
Via
Business Wire
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
September 03, 2025
From
Incyte
Via
Business Wire
Incyte (INCY) Stock Is Up, What You Need To Know
September 02, 2025
Via
StockStory
Topics
Economy
Tuesday's session: top gainers and losers in the S&P500 index
September 02, 2025
Via
Chartmill
Frequently Asked Questions
Is Incyte Corporation - Common Stock publicly traded?
Yes, Incyte Corporation - Common Stock is publicly traded.
What exchange does Incyte Corporation - Common Stock trade on?
Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Incyte Corporation - Common Stock?
The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
What is the current price of Incyte Corporation - Common Stock?
The current price of Incyte Corporation - Common Stock is 87.57
When was Incyte Corporation - Common Stock last traded?
The last trade of Incyte Corporation - Common Stock was at 10/17/25 04:00 PM ET
What is the market capitalization of Incyte Corporation - Common Stock?
The market capitalization of Incyte Corporation - Common Stock is 19.48B
How many shares of Incyte Corporation - Common Stock are outstanding?
Incyte Corporation - Common Stock has 19B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.